GSK plc stock (GB0009252882): asthma drug progress and Q1 update draw investor focus

GSK has reported first-quarter 2026 results and highlighted new data for its asthma treatment Nucala, keeping attention on its vaccines and specialty medicines strategy as US investors weigh the company’s growth and litigation risks.

GSK plc has remained in focus after publishing its first-quarter 2026 results and presenting new data for its respiratory medicine Nucala, a key asthma therapy, underscoring the group’s strategy to grow vaccines and specialty medicines, according to a results release from the company dated 04/29/2026 and follow-up medical meeting materials in late April 2026, as reported by GSK investor materials as of 04/29/2026 and coverage from Reuters as of 04/30/2026.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GSK
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: London, United Kingdom
• Core markets: Global prescription drugs and vaccines, with significant US exposure
• Key revenue drivers: Vaccines, respiratory treatments, HIV and specialty medicines
• Home exchange/listing venue: London Stock Exchange (ticker: GSK), NYSE (ticker: GSK, ADR)
• Trading currency: GBP in London, USD for ADRs

GSK plc: core business model

GSK focuses on the research, development and commercialization of prescription medicines and vaccines across infectious diseases, respiratory conditions, HIV and immunology, among other areas. The group has repositioned itself as a pure-play biopharmaceutical company following the spin-off of its consumer health business in 2022, aiming to concentrate capital and management resources on higher-margin, innovation-driven segments of the healthcare market, according to company strategy updates released in 2023 and 2024 on its website, as summarized by GSK investor presentations as of 03/2024.

The portfolio is built around four main therapeutic pillars: vaccines, specialty medicines, general medicines and HIV-focused treatments. Within vaccines, GSK markets products that target diseases such as shingles, pneumococcal infections and influenza, while its specialty medicines segment covers respiratory biologics, oncology and certain autoimmune conditions. The HIV business is operated largely through the ViiV Healthcare joint venture, in which GSK holds a majority stake, and offers a range of antiretroviral therapies. These segments collectively underpin the company’s revenue streams, with a sizeable share of sales generated in the United States, reflecting the importance of US pricing and reimbursement dynamics for the group, based on annual report disclosures published in 2024 for the 2023 financial year and discussed by Financial Times as of 03/01/2024.

GSK’s research and development model emphasizes both in-house discovery and external innovation via licensing, partnerships and selective acquisitions. The company has outlined targets to increase the proportion of its revenue coming from specialty medicines and vaccines, which typically offer higher growth potential compared with older, off-patent general medicines. It has also committed to focusing on diseases with high unmet medical need and on platforms such as mRNA, adjuvant technologies and next-generation antibody engineering, according to R&D-focused capital markets materials from 2023 and 2024 available on the company’s investor website, as referenced by Bloomberg as of 11/15/2023.

Main revenue and product drivers for GSK plc

GSK’s revenue base is diversified but increasingly concentrated in vaccines and specialty medicines. Key contributors include its shingles vaccine and certain respiratory therapies, which have been highlighted as major growth engines in recent earnings reports. For the first quarter of 2026, GSK reported year-on-year revenue growth and reiterated that vaccines and specialty medicines continued to outpace general medicines, according to its Q1 2026 results statement published on 04/29/2026, which noted performance by segment and geographic region, as cited by GSK press release as of 04/29/2026.

Respiratory therapies remain an important component of the business, and GSK has been investing in biologics such as Nucala, a treatment for severe eosinophilic asthma and related indications. New data for Nucala presented in late April 2026 at a respiratory medicine conference indicated benefits in specific patient populations, according to summaries shared by the company and reported by Reuters as of 04/30/2026. These developments support GSK’s strategy of building a portfolio of specialty medicines that can achieve premium pricing in markets such as the United States, where asthma and other chronic respiratory diseases represent significant treatment opportunities.

The HIV business, operated through ViiV Healthcare, continues to generate substantial cash flow through established therapies while newer long-acting formulations aim to defend market share against generic competition and rival branded products. Annual filings for 2023, published in early 2024, underscored the importance of HIV and vaccines as recurring revenue contributors and noted that the United States remains the group’s largest single market by sales, according to the company’s Form 20-F filed with the US Securities and Exchange Commission on 03/11/2024 and discussed by SEC filings as of 03/11/2024. This revenue mix gives GSK exposure to US healthcare spending trends, including reimbursement changes and competition from biosimilars.

In addition to organic growth, GSK occasionally uses bolt-on acquisitions and licensing deals to broaden its pipeline and product range. Over the past few years, the company has entered multiple collaborations in oncology, infectious diseases and immunology, focusing on assets that could complement its internal platforms. While no transformative merger has been announced in recent months, management has emphasized that disciplined capital allocation remains a priority, with a focus on maintaining a robust dividend while investing in R&D and targeted business development, based on comments in prior results presentations and CEO remarks captured by CNBC as of 02/01/2024.

Why GSK plc matters for US investors

For US investors, GSK offers access to a large-cap global pharmaceuticals player through American depositary receipts listed on the New York Stock Exchange, giving exposure to vaccines, respiratory medicines and HIV treatments without requiring direct access to the London market. The company’s sizeable US revenue base means that its results are influenced by US policy developments, including Medicare drug price negotiations, reimbursement decisions from major private insurers and regulatory actions by the Food and Drug Administration, as highlighted in GSK’s 2023 annual report filed on 03/11/2024 and covered by Wall Street Journal as of 03/12/2024.

GSK’s focus on vaccines and specialty medicines aligns it with secular themes such as aging populations, increased awareness of respiratory and infectious diseases, and demand for more convenient treatment regimens, including long-acting injectable formulations. These factors may contribute to long-term revenue growth but also bring execution risks related to clinical trials, regulatory approvals and manufacturing scale-up. Investors following the broader US healthcare sector often monitor GSK alongside other multinational pharmaceutical companies listed in New York and London, particularly when assessing diversification options across therapeutic areas and geographies, according to sector reviews from Morningstar as of 01/30/2024.

Currency fluctuations between the British pound and the US dollar can influence reported results for holders of the ADRs, since GSK’s primary reporting currency is sterling while dividends on the New York–listed shares are paid in US dollars. In addition, the company has faced periodic litigation over legacy products, including historical claims related to heartburn medicine Zantac, which have been closely followed by US investors because of potential financial exposure. Management has previously stated that it intends to defend its position in these cases, and the company has disclosed associated risk factors and contingent liabilities in regulatory filings, including the Form 20-F filed on 03/11/2024, as noted by SEC filings as of 03/11/2024.

Conclusion

GSK plc remains a diversified global pharmaceuticals group with an emphasis on vaccines and specialty medicines, reinforced by its Q1 2026 results and new Nucala data presented in late April 2026. The company’s strategy seeks to balance investment in innovation with shareholder returns, while its presence on the New York Stock Exchange provides US investors with access to its growth and risk profile. Key factors to monitor include the performance of its vaccines and respiratory franchises, progress in the pipeline, regulatory and litigation developments, and the impact of US healthcare policy on pricing and reimbursement. As with any healthcare stock, outcomes from clinical trials and regulatory reviews can significantly influence future earnings and share price performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.